Pharmagreen Biotech (Pharmagreen Biotech) LT-Debt-to-Total-Asset : 0.86 (As of Jun. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Pharmagreen Biotech LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Pharmagreen Biotech's long-term debt to total assests ratio for the quarter that ended in Jun. 2023 was 0.86.

Pharmagreen Biotech's long-term debt to total assets ratio increased from Jun. 2022 (0.72) to Jun. 2023 (0.86). It may suggest that Pharmagreen Biotech is progressively becoming more dependent on debt to grow their business.

Pharmagreen Biotech LT-Debt-to-Total-Asset Historical Data

The historical data trend for Pharmagreen Biotech's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmagreen Biotech LT-Debt-to-Total-Asset Chart

Pharmagreen Biotech Annual Data

Trend

Apr08

Apr09

Sep18

Sep19

Sep20

Sep21

Sep22

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.12

0.11

0.57

Pharmagreen Biotech Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.72	0.57	0.43	0.56	0.86

Pharmagreen Biotech LT-Debt-to-Total-Asset Calculation

Pharmagreen Biotech's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Sep. 2022 is calculated as

LT Debt to Total Assets (A: Sep. 2022 )	=	Long-Term Debt & Capital Lease Obligation (A: Sep. 2022 )	/	Total Assets (A: Sep. 2022 )
	=	0.119	/	0.209
	=

Pharmagreen Biotech's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2023 is calculated as

LT Debt to Total Assets (Q: Jun. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2023 )	/	Total Assets (Q: Jun. 2023 )
	=	0.12	/	0.14
	=	0.86

Pharmagreen Biotech (OTCPK:PHBI) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Pharmagreen Biotech LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Pharmagreen Biotech's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmagreen Biotech (Pharmagreen Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharmagreen Biotech Inc (OTCPK:PHBI) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

112 North Curry Street, Carson, NV, USA, 89703

Website

https://www.pharmagreen.ca

Pharmagreen Biotech Inc is a biotech science company with specialized products and services in the cannabis industry. The company plans to produce and sell tissue culture plantlets and cannabis oil. Its line of nutraceutical products is a proprietary blend of therapeutic plants and mushrooms. It is developing its business model beyond just cannabis, and is focused on near term revenues from its proprietary blend of therapeutic plants and fungi, a nutraceutical wellness product. Utilizing the Company's expertise in plant genetics, Its transgenic program uses the newest technology available to research and create nutraceuticals, protein-based vaccines, and daily supplements with the potential to improve lives and address a wide variety of disease conditions.